公开(公告)号：US20240391931A1

公开(公告)日：2024-11-28

申请号：US18294280

申请日：2022-08-04

Applicant: Bristol-Myers Squibb Company

Inventor： Laura Akullian D'Agostino ,  Xinchao Chen ,  Claudio Emundo Chuaqui ,  Hormoz Mazdiyasni ,  Guobin Miao ,  Deqiang Niu

IPC: C07D495/14 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/69 ,  A61P35/00 ,  C07D471/14 ,  C07D519/00 ,  C07F5/02

Abstract: Provided herein are tricyclic fused pyrimidine compounds, and pharmaceutically acceptable salts thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

公开(公告)号：US20240360235A1

公开(公告)日：2024-10-31

申请号：US18628224

申请日：2024-04-05

Applicant: Bristol-Myers Squibb Company ,  Celldex Therapeutics, Inc.

Inventor： Vladimir CORIC ,  Tibor KELER ,  Thomas DAVIS

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/0011 ,  A61K39/001129 ,  A61K39/00115 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76

Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

公开(公告)号：US12129264B2

公开(公告)日：2024-10-29

申请号：US17415237

申请日：2019-12-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Roxana F. Schlam ,  Nicolas Cuniere ,  Victoria A. Mbachu ,  Zhongping Shi ,  Petinka I. Vlahova

IPC: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265

CPC classification number: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265 ,  C07B2200/13

Abstract: The present invention relates to co-crystals of the compound of formula (I), wherein the co-former molecule is succinic acid or citric acid, processes for the preparation of the co-crystal, pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.

公开(公告)号：US12110337B2

公开(公告)日：2024-10-08

申请号：US17045143

申请日：2019-04-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Li-Sheng Lu ,  Mark J. Selby ,  Alan J. Korman ,  Shrikant Deshpande ,  Mohan Srinivasan ,  Jun Zhang ,  Haichun Huang ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina Deyanova

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K39/39541 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

公开(公告)号：US12110290B2

公开(公告)日：2024-10-08

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20240317769A1

公开(公告)日：2024-09-26

申请号：US18550234

申请日：2022-03-14

Applicant: Bristol-Myers Squibb Company

Inventor： Brian Edward FINK ,  Robert Joseph CHERNEY ,  Khehyong NGU ,  Upender VELAPARTHI ,  Wayne David VACCARO ,  Zheming RUAN ,  Lan-Ying QIN ,  Pravin S. SHIRUDE ,  Hasibur RAHAMAN

IPC: C07D487/08 ,  A61K31/517 ,  C07D471/08 ,  C07D519/00

CPC classification number: C07D487/08 ,  A61K31/517 ,  C07D471/08 ,  C07D519/00

Abstract: The present disclosure relates to KRAS inhibitors. Methods of treating cancers using the compounds are also provided.

公开(公告)号：US20240316161A1

公开(公告)日：2024-09-26

申请号：US18482248

申请日：2023-10-06

Applicant: Bristol-Myers Squibb Company

Inventor： Sharon CLOAD ,  Linda ENGLE ,  Dasa LIPOVSEK ,  Malavi MADIREDDI ,  Ginger Chao RAKESTRAW ,  Joanna SWAIN ,  Wenjun ZHAO ,  Hui WEI ,  Aaron P. YAMNIUK ,  Vidhyashankar RAMAMURTHY ,  Alexander T. KOZHICH ,  Martin J. CORBETT ,  Stanley Richard KRYSTEK, JR.

IPC: A61K38/39 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  C07K14/435 ,  C07K14/765 ,  C07K14/78 ,  C07K14/79 ,  C07K16/18 ,  C07K16/46 ,  G01N33/74

CPC classification number: A61K38/39 ,  A61K38/17 ,  A61K38/1709 ,  A61K45/06 ,  A61K47/60 ,  A61K47/642 ,  C07K14/435 ,  C07K14/765 ,  C07K14/78 ,  C07K14/79 ,  C07K16/18 ,  C07K16/46 ,  G01N33/74 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/31

Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.

公开(公告)号：US12097241B2

公开(公告)日：2024-09-24

申请号：US17573238

申请日：2022-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: A61K38/18 ,  A61K38/22 ,  C07K1/107 ,  C07K14/64 ,  A61K38/00 ,  A61K45/06 ,  A61K47/64 ,  A61P9/00

CPC classification number: A61K38/18 ,  A61K38/2221 ,  C07K1/1077 ,  C07K14/64 ,  A61K38/00 ,  A61K45/06 ,  A61K47/64 ,  A61P9/00

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US20240309019A1

公开(公告)日：2024-09-19

申请号：US18530405

申请日：2023-12-06

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

CPC classification number: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII):




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US12060341B2

公开(公告)日：2024-08-13

申请号：US17888600

申请日：2022-08-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Benjamin P. Vokits ,  Scott A. Shaw

IPC: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D471/04

Abstract: The present invention provides compounds of Formula (I):




or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.